Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Status:
RECRUITING
Trial end date:
2033-12-30
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University